Inactive Instrument

CohBar Inc Stock price Toronto S.E.

Equities

COBu

US19249J1097

Biotechnology & Medical Research

End-of-day quote Toronto S.E.
- 0.00% Intraday chart for CohBar Inc
Sales 2021 - Sales 2022 - Capitalization 4.93M 0
Net income 2021 -15M - Net income 2022 -12M - EV / Sales 2021 -
Net cash position 2021 25.88M 0 Net cash position 2022 15.74M 0 EV / Sales 2022 -
P/E ratio 2021
-1.51 x
P/E ratio 2022
-0.4 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 84.91%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 22-01-03
Members of the board TitleAgeSince
Director/Board Member 63 Nov. 05
More insiders
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
More about the company
  1. Stock
  2. Equities
  3. Stock CohBar, Inc.
  4. Stock CohBar Inc - Toronto S.E.